Molecular detection of azithromycin resistance mechanisms in typhoidal salmonellae  by Sharma, P. et al.
17th International Congress on Infectious Diseases / International Journal of Infectious Diseases 45S (2016) 1–477 127
weight ligands, few thiazole coupled with Schiff’s base and their
metal complexes were synthesized and biologically evaluated.
Methods & Materials: A novel series of thiazole derivatives
were rationally designed by Computer Assisted Drug Design
(CADD) approach (VLife Science®). The optimized scaffold was
synthesized inmultiple steps fromthiosemicarbazide andwas suit-
ably cyclized to get corresponding active 2,4-di-substitued thiazole
derivatives. Metal complexes of thiazoles were further prepared
using salts of d-block compounds (copper, nickel and cobalt) as per
protocol designed in our laboratory. The modern analytical tech-
niques (UV-Vis, IR, NMR, MS, RS, XRD, AAS, MM, MC) revealed that
the results were in full agreement with their assigned chemical
structures. All the synthesized compounds were screened for their
anti-microbial activity according to standard protocol against bac-
terial strains (E. coli, MTCC-1687; S. aureus, MTCC-2940; B. subtilis,
MTCC-441; and K. pneumonia, MTCC-3040). The nucleolytic activ-
ity of compounds and metal complexes were evaluated using gel
electrophoresis employing E. coli plasmid pBR322.
Results: Among them, para-substituted (halogenated) thiazoles
exhibited excellent anti-bacterial activity against E. coli, S. aureus,
and K. pneumonia. Nearly all compounds exhibited moderate to
high nuclease activity. The copper complexes showed moderate
nuclease activity while cobalt and nickel complexes displayed
excellent nuclease activity. The in silico docking study performed
revealed the binding orientations of these compounds at active site
amino acid residues ASN 165 and GLU 40 (PDB ID: 1AHP), amino
acid residues TYR 151 and GLY 18 (PDB ID: 2C44) and amino acid
residues ARG 73 and ASP 76 (PDB ID: 1K6W) of crystal structure of
E. coli metabolic enzymes.
Conclusion: From this study, it can be concluded that the novel
molecules have tremendous anti-microbial and nuclease activity.
This research helps in understanding mechanism of action of thia-
zole based anti-microbials and it may possibly be used as template
for searching potent anti-microbial agents in future.
http://dx.doi.org/10.1016/j.ijid.2016.02.314
Type: Poster Presentation
Final Abstract Number: 41.121
Session: Poster Session I
Date: Thursday, March 3, 2016
Time: 12:45-14:15
Room: Hall 3 (Posters & Exhibition)
Incidence of SHV and CTX-M Extended
spectrum -lactamases producing gram
negative bacterial isolates from antenatal
mother with asymptomatic bacteriuria
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Background: Asymptomatic bacteriuria (ABU) occurs in 2 to
10% of cases during pregnancy and the risk of onset of bacteriuria
is maximum between 9th to 17th week of gestation. ABU will lead
to adverse anomalies if left untreated such as acute pyelonephri-
tis, low birth weight infants (LBW) and premature delivery. The
incidence of Extended Spectrum Beta-Lactamases (ESBLs) such as
TEM-1, SHV-1 and CTX-M type producing uropathogenic bacteria
have been increasing over years. Thus this study was carried out
to analyze the population of ESBL producing MDR Gram nega-
tive bacteria and to ascertain the most prevalent ESBL gene in our
geographical region among antenatal women with asymptomatic
bacteriuria.
Methods & Materials: A total of 637 asymptomatic antenatal
mothers who consecutively attended the Obstetrics OPD between
April and September 2015 were included in this study. Their mid-
stream urine samples were collected during the 16th week of
gestationandprocessed in theDepartmentofClinicalMicrobiology,
MGMCRI following standard methods. Gram negative pathogens
were isolated and phenotypically conﬁrmed for ESBL production.
All those ESBL positive isolates were screened by PCR for the pres-
ence of blaCTX-M, blaSHV and blaTEM with speciﬁc primers and the
amplicons were subjected to sequencing.
Results: Out of 637 antenatalmothers with asymptomatic bac-
teriuria, 54 urine samples were not included due to improper
sample collection and 268 samples were found to be sterile.
Remaining 315 samples showed signiﬁcant growth of single
pathogenic bacteria. Among these, 44 were Gram positive isolates
and 271were Gram negative pathogens. ESBL productionwas phe-
notypically observed among 35% (n=95) of these GNB. Out of these
95 ESBL isolates, 73% were MDR isolates, none of them carried
blaTEM and the presence of blaCTX-M and blaSHV were observed in
69.4% and 20% of isolates respectively. All the blaCTX-M and blaSHV
amplicons were conﬁrmed through sequencing followed by BLAST
analysis (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Conclusion: Presence of blaCTX-M and blaSHV genes reﬂects their
prevalence among the community. Periodic and continuous ante-
natal follow-uponly can reduce the complications of asymptomatic
bacteriuria among antenatalmothers. This study urges the need for
the regional antimicrobial practicing policy by the stakeholders to
implement and to monitor.
http://dx.doi.org/10.1016/j.ijid.2016.02.315
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Background: Antibiotic resistance in enteric fever continues to
pose major therapeutic challenge with increase in ciproﬂoxacin
resistance. Azithromycin has been used to treat enteric fever as
an alternate treatment option without any guidelines for labora-
tory interpretation. In 2015 issue CLSI has added breakpoints for
testing azithromycin susceptibility in typhoidal Salmonellae. We
aimed to assess the prevalence of resistance to azithromycin in S.
Typhi and S. Paratyphi A in a collection of strains to characterize
the mechanisms underlying resistance.
Methods & Materials: A total number of 224 S. Typhi and S.
Paratyphi A isolates were available in the cryopreservated stock
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whichwere isolated from the patients presentedwith enteric fever
during 1990 to 2015. Antimicrobial susceptibility testing was done
by disk diffusion method as per CLSI 2015 and MICs were deter-
mined by E test method as per manufacturer’s guidelines (AB
Biodisk, Sweden).
For molecular chaeacterization of azithromycin resistance, PCR
detection was done to screen for the presence of genes responsible
for azithromycin resistance i.e, ereA, ereB, ermB, mefA, mphA, mphB
and mphD from plasmid and genomic DNA. Sequence analysis was
done to detect mutations in acrR, rlpD and rlpV from genomic DNA.
Results: It was observed that 96.11% of the isolates were sus-
ceptible to azithromycin using disk diffusion method. There was
a linear trend observed with time in azithromycin susceptibility
(2 =5.240, P value <0.02). The MIC 50 and MIC 90 values were
6 and 12g/ml respectively while the resistance breakpoint is
≥16g/ml. There was no acquired gene for macrolide resistance
in plasmid or genomic DNA of any isolate and DNA sequences of
acrR, rlpD and rlpV genes did not show any mutations.
Total use of azithromycin in pediatric population was only
13,125 mg given to 16 patients in 2014-15.
Conclusion: Azithromycin is a good promising agent against
typhoid fever on the basis of MIC distribution in India at present.
More studies are required to study the use of azithromycin in
complicated infections as at present it is beingusedonly for uncom-
plicated cases.
http://dx.doi.org/10.1016/j.ijid.2016.02.316
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In vitro and in vivo activity of “compound A”
against gram-positive and -negative pathogens
including MDR strains
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Background: Compound A is a novel Topo-IV inhibitor with
broad spectrum activity against both Gram- negative and posi-
tive pathogens, especially Pseudomonas aeruginosa, Acinetobacter.
baumannii, Escherichia coli, and MRSA. The present study focuses
on its in vitro activity, in vivo efﬁcacy and pharmacokinetics-
pharmacodynamics in murine infection models.
Methods & Materials: MIC were determined by CLSI method
against 135 bacterial strains including ATCC and clinical isolates of
(sensitive and MDR) Pseudomonas aeruginosa (n=55), A. baumannii
(n=25), Escherichia coli (n=30) andMRSA (n=25) includingMDR iso-
lates. Time kill study was performed against these pathogens. The
therapeutic efﬁcacywas evaluated using amouse pulmonary infec-
tion model. The pharmacokinetics-pharmacodynamics (PK-PD)
parameters against P. aeruginosa were determined in neutropenic
murine thigh infection model.
Results: Compound A showed MIC90 of 4, 0.5, 0.25 and 0.25
g/ml against P. aeruginosa, A. baumannii, E. coli and MRSA, respec-
tively. In murine pulmonary infection model, it showed killing
potential against P. aeruginosa and A. baumannii and reduced the
pulmonary bacterial number in a dose-dependent manner. In the
PK-PDstudy, theefﬁcacyofCompoundAagainstP. aeruginosa infec-
tion was correlated with AUC/MIC (R2 =0.89) and Time above MIC
(R2 = 0.93) more than Cmax/MIC (R2 =0.12).
Conclusion: Compound A exhibited excellent broad spectrum
of activity against Gram- positive and negative pathogens. Hence,
it could be a promising investigational candidate for antibacterial
therapy.
http://dx.doi.org/10.1016/j.ijid.2016.02.317
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Background: The emergence of bacterial resistance to antibi-
otics is a major concern; therefore, it is critical to develop new
antibiotics with novel modes of action. FtsZ is an essential bac-
terial guanosine triphosphatase (GTPase) play an essential role in
bacterial cell division, and its homologs are present in almost all
eubacteria, archaea and mammalian that polymerizes and assem-
bles into a ring to initiate cell division. Compound-A is a novel
FtsZ inhibitor with potent and selective in vitro bactericidal activ-
ity against methicillin-susceptible Staphylococcus aureus (MSSA)
methicillin-resistant Staphylococcus aureus (MRSA).
Methods & Materials: The antibacterial activities were deter-
mined by the CLSI micro-broth dilution methods. In vivo efﬁcacy
was evaluated in mouse model of infection caused by MRSA.
Results: Compound-A showed potent activity against various
clinical isolates of MSSA and MRSA. The MIC90s of Compound-
A against MRSA was 2g/mL, respectively. Compound-A showed
the potent inhibitory activity against S. aureus FtsZ enzyme >100
fold selection against its mammalian homolog porcin -tubulin.
Compound- A showed bactericidal activity against MRSA and
showed synergy with carbapenem drugs. Compound-A was efﬁ-
cacious in mouse infection model.
Conclusion: Compound-A showed potent activity against mul-
tidrug resistantMRSAstrainsandbactericidal activity. These results
suggest that Compound-A is suitable for further investigation.
http://dx.doi.org/10.1016/j.ijid.2016.02.318
